International Experts Gather in Málaga for the 24th Annual Advances in Hepatology Conference

The 24th Annual Conference on Advances in Hepatology will take place in Málaga on May 15 and 16, 2025, at the Aula Magna of the Faculty of Medicine at the University of Málaga. This event, which has established itself as a scientific reference at the national level, will bring together prominent national and international experts to discuss the latest developments in the diagnosis and treatment of various liver diseases, including chronic hepatitis B and C, metabolic dysfunction-associated fatty liver disease (MASLD), and liver cirrhosis.

Organized by the Department of Medicine and the Digestive System Service of the “Virgen de la Victoria” University Hospital, in collaboration with the Biomedical Research Institute of Málaga (IBIMA), this conference is supported by prominent entities such as Abbvie, AstraZeneca, Madrigal Pharma, Ipsen, Novo Nordisk, Roche, Echosens, Orphalan, and Gilead. The Spanish Association for the Study of the Liver and the Andalusian Society of Digestive Pathology, among others, also collaborate.

The event expects to gather around a hundred participants in person, as well as a virtual audience composed of healthcare professionals, specialists in various disciplines, residents, and doctoral students. During the conference, knowledge exchange spaces will be created on advancements in personalized medicine for patients with MASLD, drug-induced liver toxicity, and updates on the treatment of conditions such as Wilson’s disease, primary biliary cholangitis, and cholangiocarcinoma.

One of the most anticipated lectures will be delivered by Dr. Miguel Ángel Martínez, from the University of Navarra and the Harvard T.H. Chan School of Public Health, a recognized expert in public health and the Mediterranean diet as a preventive tool for diseases.

Dr. Raúl J. Andrade Bellido, director and organizer of the event, emphasizes that this conference represents a “unique opportunity to share knowledge and explore solutions” to contemporary challenges in hepatology. Recognized internationally for his work on drug-induced hepatotoxicity, Dr. Andrade underscores the importance of scientific collaboration to advance the treatment of liver diseases.

Topics for discussion will include the current epidemiology of liver diseases, the impact of diet and alcohol consumption, as well as evidence-based dietary guidelines for the prevention and management of these conditions. Participants will also analyze therapeutic strategies for controlling portal hypertension in hepatocarcinoma and new developments in the treatment of systemic hepatocellular carcinoma.

This event, supported by the CIBERehd funded by ISCIII and other organizations, promises to be a significant milestone in the professional hepatology community, facilitating constructive dialogue on the most effective strategies to address current issues in managing liver diseases.